BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer
Andreas E. Moor,
Pascale Anderle,
Claudio Cantù,
Patrick Rodriguez,
Norbert Wiedemann,
Frédérique Baruthio,
Jürgen Deka,
Sylvie André,
Tomas Valenta,
Matthias B. Moor,
Balázs Győrffy,
David Barras,
Mauro Delorenzi,
Konrad Basler,
Michel Aguet
Affiliations
Andreas E. Moor
Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne (EPFL), School of Life Sciences, CH-1015 Lausanne, Switzerland
Pascale Anderle
SIB Swiss Institute of Bioinformatics, CH-1015 Lausanne, Switzerland
Claudio Cantù
Institute of Molecular Life Sciences, Universität Zürich, CH-8057 Zürich, Switzerland
Patrick Rodriguez
Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne (EPFL), School of Life Sciences, CH-1015 Lausanne, Switzerland
Norbert Wiedemann
Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne (EPFL), School of Life Sciences, CH-1015 Lausanne, Switzerland
Frédérique Baruthio
Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne (EPFL), School of Life Sciences, CH-1015 Lausanne, Switzerland
Jürgen Deka
Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne (EPFL), School of Life Sciences, CH-1015 Lausanne, Switzerland
Sylvie André
Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne (EPFL), School of Life Sciences, CH-1015 Lausanne, Switzerland
Tomas Valenta
Institute of Molecular Life Sciences, Universität Zürich, CH-8057 Zürich, Switzerland
Matthias B. Moor
Department of Pharmacology and Toxicology, University of Lausanne, CH-1005 Lausanne, Switzerland
Balázs Győrffy
MTA TTK Lendület Cancer Biomarker Research Group, 2nd Dept. of Pediatrics, Semmelweis University, Budapest, Hungary
David Barras
SIB Swiss Institute of Bioinformatics, CH-1015 Lausanne, Switzerland
Mauro Delorenzi
SIB Swiss Institute of Bioinformatics, CH-1015 Lausanne, Switzerland
Konrad Basler
Institute of Molecular Life Sciences, Universität Zürich, CH-8057 Zürich, Switzerland
Michel Aguet
Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne (EPFL), School of Life Sciences, CH-1015 Lausanne, Switzerland
BCL9/9L proteins enhance the transcriptional output of the β-catenin/TCF transcriptional complex and contribute critically to upholding the high WNT signaling level required for stemness maintenance in the intestinal epithelium. Here we show that a BCL9/9L-dependent gene signature derived from independent mouse colorectal cancer (CRC) models unprecedentedly separates patient subgroups with regard to progression free and overall survival. We found that this effect was by and large attributable to stemness related gene sets. Remarkably, this signature proved associated with recently described poor prognosis CRC subtypes exhibiting high stemness and/or epithelial-to-mesenchymal transition (EMT) traits. Consistent with the notion that high WNT signaling is required for stemness maintenance, ablating Bcl9/9l-β-catenin in murine oncogenic intestinal organoids provoked their differentiation and completely abrogated their tumorigenicity, while not affecting their proliferation. Therapeutic strategies aimed at targeting WNT responses may be limited by intestinal toxicity. Our findings suggest that attenuating WNT signaling to an extent that affects stemness maintenance without disturbing intestinal renewal might be well tolerated and prove sufficient to reduce CRC recurrence and dramatically improve disease outcome.